Back to Search

VRISHALI SUMAN, MD

MD

Family Medicine Physician

NPI: 1194202705IndividualAccepts Medicare

Specialties, Licenses & Credentials

Student in an Organized Health Care Education/Training Program

Student in an Organized Health Care Education/Training Program

Code: 390200000X

309755(LA)
Family Medicine PhysicianPrimary

Family Medicine

Code: 207Q00000X

MD17386(RI)

CMS Specialties

PrimaryFAMILY PRACTICE

Education

OTHER

Class of 2016

Research & Publications (20)

Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
PMID 19648970·Bone Marrow Transplant·2010
3-trial
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
PMID 19090009·Cancer·2009
3-trial
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
PMID 19349549·J Clin Oncol·2009
3-trial
Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.
PMID 19487378·J Clin Oncol·2009
3-trial
A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study.
PMID 19060590·Am J Clin Oncol·2008
3-trial
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
PMID 18794098·Clin Cancer Res·2008
8-other
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
PMID 18235113·J Clin Oncol·2008
8-other
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
PMID 18413808·Mol Cancer Ther·2008
8-other
Lack of publication bias related to results from trastuzumab study.
PMID 18722859·Lancet·2008
8-other
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
PMID 18250349·J Clin Oncol·2008
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
239 CRANSTON ST
PROVIDENCE, RI 02907

Quick Facts

NPI
1194202705
Entity Type
Individual
Gender
Female
Medicare
Accepted
Specialties
2
Locations
1
Years in Practice
10
Publications
20

Are you this provider?

Claim Your Profile